Keap1-Nrf2

Keap1-Nrf2-IN-15 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting IC50 values of 77 nM in fluorescence polarization (FP) assays and 2.5 nM in time-resolved Förster resonance energy transfer (TR-FRET) assays. This compound enhances the activation of the Nrf2 pathway, which plays a critical role in cellular defense mechanisms against oxidative stress and inflammation. Keap1-Nrf2-IN-15 is a valuable tool for research applications focused on neuroprotection, cancer therapy, and the modulation of antioxidant responses.

Keap1-Nrf2-IN-12 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting an IC50 value of 2.30 µM. This compound effectively modulates the Nrf2 signaling pathway, which is critical for cellular defense against oxidative stress. Additionally, Keap1-Nrf2-IN-12 demonstrates metabolic stability in human liver microsomes, making it a valuable tool for research applications focused on oxidative stress response and related therapeutic targets.

Carlinoside is a flavone glycoside that exhibits hepatoprotective properties. It effectively reduces hepatic bilirubin accumulation by enhancing bilirubin-UDP-glucuronosyltransferase (UGT) activity through the activation of Nrf2 gene expression. This compound holds potential for the management of hyperbilirubinemia associated with liver dysfunction.

Keap1-Nrf2-IN-22 is a selective inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 42.2 nM for Keap1. This compound is valuable for investigating the regulatory mechanisms of oxidative stress and cytoprotection in cellular environments. Key research applications include the study of acute lung injury (ALI) and cerebral ischemia/reperfusion (I/R) injury, where modulation of the Nrf2 pathway may provide therapeutic insights.

Keap1-IN-2 is a potent KEAP1 inhibitor with an IC50 of 2 nM, designed to indirectly activate Nrf2. By inhibiting KEAP1, this compound enhances cellular antioxidant capacity and promotes the accumulation and nuclear translocation of Nrf2, preventing its degradation. Keap1-IN-2 is applicable in research exploring diseases linked to oxidative stress, including inflammatory bowel disease, Crohn's disease, and immune disorders such as ulcerative colitis.

TPNA10168 is an Nrf-2 activator that enhances the Keap1-Nrf2-ARE signaling pathway. It exhibits neuroprotective properties against oxidative stress-induced cellular damage and significantly downregulates the expression of inflammatory genes such as TNF-α, IL-1β, IL-6, and iNOS. TPNA10168 is suitable for research applications focused on anti-inflammatory responses and neurological disorders.

WN1316 is an orally active antioxidant agent that exhibits neuroprotective properties. It is primarily utilized in research focused on amyotrophic lateral sclerosis (ALS), making it a valuable tool for studying neurodegenerative diseases and the underlying mechanisms of oxidative stress in neuronal cells.

CPDT is a potent activator of the transcription factor Nrf2, which plays a crucial role in cellular defense mechanisms. It significantly induces the expression of phase 2 enzymes, including glutathione S-transferase, NAD(P)H:quinone:oxidoreductase 1, and glutamate cysteine synthetase. Research demonstrates that CPDT enhances glutathione levels in rat bladder in vivo and in cultured bladder cells in vitro, highlighting its potential applications in studies of oxidative stress and antioxidant responses.

Keap1-Nrf2-IN-17 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction. This compound enhances the activation of the Nrf2 pathway, which plays a critical role in cellular defense against oxidative stress and inflammation. Keap1-Nrf2-IN-17 is valuable for research applications focused on understanding the mechanisms of oxidative stress response and exploring therapeutic options for related diseases.

S21-1011 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.059 μM for equine BChE and 0.162 μM for human BChE. This compound demonstrates effective blood-brain barrier permeability and favorable pharmacokinetic properties. Additionally, S21-1011 exhibits anti-inflammatory activity by activating the keap1-Nrf2-ARE signaling pathway, with an EC50 of 23.48 μM for antioxidant response element activation. Its potential to ameliorate cognitive impairments in murine models of Alzheimer’s disease makes it relevant for neurodegenerative research applications.

AChE/Nrf2 Modulator 1 is an orally active compound that targets both acetylcholinesterase (AChE) and the nuclear factor erythroid 2-related factor 2 (Nrf2). It exhibits significant Nrf2 inductive activity along with potent AChE inhibitory effects, presenting IC50 values of 0.07 μM for eel AChE and 0.38 μM for human AChE. This compound is primarily utilized in research focused on Alzheimer's disease, providing insights into neuroprotective mechanisms and cholinergic system modulation.

VVD-130037 is a covalent molecular glue and allosteric degrader of NRF2, targeting the KEAP1 protein. By binding to KEAP1, it enhances the formation of the KEAP1-CUL3 E3 ligase complex, leading to increased ubiquitination and subsequent degradation of NRF2. This compound demonstrates KEAP1 target-binding activity in both in vitro assays and mouse models, making it a useful tool in research involving NRF2-dependent cancers, solid tumors with KEAP1 mutations, and advanced solid tumors.

CBR-470-1 is a selective inhibitor of phosphoglycerate kinase 1 (PGK1), a key enzyme in the glycolytic pathway. This compound also acts as a non-covalent activator of Nrf2, enhancing the cellular defense mechanisms against oxidative stress. In cellular models, CBR-470-1 has demonstrated protective effects against MPP+-induced cytotoxicity in SH-SY5Y neuronal cells by activating the Keap1-Nrf2 signaling pathway. This dual functionality makes CBR-470-1 a valuable tool for research in metabolic regulation and neuroprotection.

Safranal, the primary aromatic compound derived from Saffron (Crocus sativus), serves as a key target for research involving its neuroprotective and anti-inflammatory properties. Its potential applications in the study of neurodegenerative diseases, particularly Parkinson's disease, make it a valuable reagent for chemical research. Safranal's unique characteristics also support investigations into its effects on sensory perception and mood enhancement.

Nrf2 activator-2 (compound O15) is a potent Nrf2 agonist that functions by disrupting the interaction between Keap1 and Nrf2, thereby promoting Nrf2 activation. With an EC50 of 2.9 μM in 293 T cells, this compound significantly reduces the levels of ubiquitinated Nrf2, enhancing its stability and nuclear translocation. Nrf2 activator-2 is valuable in studies exploring oxidative stress response, cellular defense mechanisms, and potential therapeutic applications in diseases associated with Nrf2 dysregulation.

Dibenzoylmethane is a potent activator of the Keap1-Nrf2 pathway. By promoting the dissociation of Nrf2 from Keap1, it facilitates the nuclear translocation of Nrf2, leading to enhanced expression of antioxidant and cytoprotective genes. This compound has potential applications in cancer prevention research and studies focused on mitigating oxidative stress.

I-152 is a bifunctional conjugate designed as an NRF2 and ATF4 activator. This compound enhances cellular antioxidant responses and promotes cytoprotective signaling pathways. Additionally, I-152 exhibits anti-proliferative properties, making it a valuable tool for research in cancer biology and oxidative stress studies.

DDO-7263 is a potent activator of Nrf2, functioning primarily through its binding to Rpn6, which inhibits the assembly of the 26S proteasome and prevents the degradation of ubiquitinated Nrf2. This results in the translocation of Nrf2 into the nucleus, thereby enhancing its transcriptional activity. Additionally, DDO-7263 has been shown to inhibit the activation of the NLRP3 inflammasome, demonstrating significant anti-inflammatory properties. It holds promise for research applications in neurodegenerative diseases, such as Parkinson's disease.

Eriodictyol-7-O-glucoside is a flavonoid that functions as an Nrf2 activator. It demonstrates potent scavenging activity against hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. This compound enhances the nuclear localization of Nrf2, leading to the induction of Nrf2/ARE-dependent gene expression. Eriodictyol-7-O-glucoside offers protective effects against oxidative stress induced by oxygen and glucose deprivation, and exhibits neuroprotective properties in models of focal cerebral ischemia. It is valuable for research in stroke and neuroprotection studies.

Monoethyl fumarate is the monoethyl ester of fumaric acid and serves as an activator of the Nrf2 pathway. This compound exhibits significant potential for antioxidant activity and may play a crucial role in cellular defense mechanisms. Its applications extend to research involving neuroprotection and inflammation modulation, as well as in the exploration of therapeutic strategies for various diseases. Additionally, monoethyl fumarate is utilized as a preservative and polymerization agent for macromolecular materials.

NXPZ-2 is an orally active inhibitor of the Keap1-Nrf2 protein-protein interaction with a Ki value of 95 nM and EC50 values of 120 and 170 nM. It has demonstrated the ability to dose-dependently mitigate Aβ[1-42]-induced cognitive dysfunction and improve brain tissue pathology in Alzheimer's disease models by enhancing neuronal quantity and function. NXPZ-2 functions by inhibiting oxidative stress through increased expression of Nrf2 and promoting its translocation from the cytoplasm to the nucleus, supporting research into Keap1-Nrf2 interactions and Alzheimer’s disease.

Nrf2 activator-3 is a potent activator of the NF-E2-related factor 2 (Nrf2) pathway. This compound enhances antioxidant response element (ARE) transcriptional activity, promoting the expression of various cytoprotective genes. Nrf2 activator-3 is primarily utilized in research focusing on cerebral ischemic injury, where it may help elucidate mechanisms of neuroprotection and potential therapeutic strategies.

CBR-470-2 is a glycine-substituted analog that functions as an NRF2 activator. This compound significantly enhances NRF2 signaling pathways, making it a valuable tool for research into metabolic modulation, particularly glycolysis. Its ability to influence key cellular processes positions CBR-470-2 as an important reagent for exploring the roles of oxidative stress and inflammation in various biological systems.

Keap1-Nrf2-IN-13 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI), exhibiting an IC50 of 0.15 μM. This compound effectively disrupts the binding of Keap1 to Nrf2 by establishing hydrogen bonds with critical polar residues such as Asn414, Arg415, Arg483, and Gln530. Keap1-Nrf2-IN-13 is valuable for research focused on oxidative stress-related conditions and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and various cancers.

Toralactone is a selective inhibitor of the Keap1-Nrf2 pathway, which plays a crucial role in cellular antioxidant defense mechanisms. Originating from Cassia obtusifolia, Toralactone exhibits significant hepatoprotective effects mediated through Nrf2 activation. This compound is suitable for research applications focused on oxidative stress, hepatotoxicity, and the modulation of antioxidant responses in various biological systems.

Nrf2 activator-12 is a potent activator of the Keap1-Nrf2 pathway, with an EC50 value of 83.5 nM. This compound demonstrates significant pharmacological effects, including the ability to reverse disease progression and mitigate demyelination in an experimental autoimmune encephalomyelitis mouse model. Nrf2 activator-12 is valuable for studies exploring oxidative stress responses and potential neuroprotective strategies in various neurological disorders.

Keap1-Nrf2-IN-9 is a selective inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI) with a reported IC50 of 0.575 μM. This compound enhances the expression of Nrf2 target genes, including heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and the modulatory and catalytic subunits of glutamate-cysteine ligase (Gclc and Gclm). Keap1-Nrf2-IN-9 exhibits low cytotoxicity in ARPE19 cells, making it a valuable tool for studies focused on oxidative stress and cellular defense mechanisms.

Nrf2 activator-1 is a potent activator of the NF-E2 related factor 2 (Nrf2), a key regulator of cellular antioxidant response. It demonstrates significant biological activity in modulating oxidative stress and inflammation. This compound is valuable for research applications related to chronic obstructive pulmonary disease (COPD), asthma, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and pulmonary fibrosis, facilitating the exploration of therapeutic interventions in these conditions.

MIND4-17 is a selective NRF2 activator that covalently modifies the C151 residue of Keap1. By disrupting the association between Keap1 and Nrf2, MIND4-17 promotes Nrf2 protein stabilization and subsequent nuclear translocation, enhancing the cellular antioxidant response. This compound demonstrates strong antioxidant activity and is valuable for research applications focused on oxidative stress and related pathways.

VVD 065 is an allosteric modulator of the Keap1-Cul3 E3 ligase complex that functions as a molecular glue. By activating KEAP1, VVD 065 promotes the degradation of NRF2, an essential regulator of antioxidant defenses. This compound has demonstrated the ability to inhibit tumor growth in non-small cell lung cancer and esophageal squamous cell carcinoma xenograft models. VVD 065 serves as a valuable tool for research on cancer biology and therapeutic strategies targeting oxidative stress responses.

BPK-29 hydrochloride is a selective agent that disrupts interactions between the atypical orphan nuclear receptor NR0B1 and its protein partners, such as RBM45 and SNW1, through covalent modification of cysteine residue C274. This compound has been shown to inhibit anchorage-independent growth in KEAP1-mutant cancer cell lines, making it a valuable tool for studying the biological functions of NR0B1 and its role in cancer development. BPK-29 hydrochloride is essential for research on targeted therapies in oncology and the mechanisms underlying cancer cell proliferation.

Hydroxycitric acid (tripotassium) is a potent activator of the Nrf2, AMPK, and mTOR signaling pathways. It enhances the expression of antioxidant enzymes, elevates glutathione levels, and inhibits ferroptosis, thereby providing protection against oxidative stress and promoting cellular health. This compound is actively engaged in regulating renal and pulmonary vascular functions and is also implicated in the induction of apoptosis in cancer cells through cell cycle arrest and DNA fragmentation. Its multi-target bioactivity makes it a valuable tool in research focused on oxidative stress, cancer biology, and metabolic regulation.

(R,S,R)-ML334 is the isomer of ML334, serving as a valuable experimental control in research. This compound acts primarily as a cell-permeable activator of NRF2 by inhibiting the Keap1-NRF2 protein-protein interaction. With a binding affinity of 1 µM to the Kelch domain of Keap1, (R,S,R)-ML334 enhances NRF2 expression, promotes its nuclear translocation, and induces antioxidant response elements (ARE) activity, making it significant for studies related to oxidative stress and cellular defense mechanisms.

Chikusetsusaponin IVa is an orally active anti-inflammatory agent that targets YAP, demonstrating a binding affinity with a KD value of 0.388 mM. This compound effectively reduces the expression of inflammatory mediators such as IL-6, IL-10, and COX-2, while modulating nitric oxide production and promoting reactive oxygen species generation. Additionally, Chikusetsusaponin IVa induces apoptosis, inhibits MAPK and TAZ signaling pathways, and regulates Nrf2 and JAK/STAT pathways. It exhibits potential as an anti-H9N2 avian influenza virus agent and demonstrates anti-cancer properties, along with hepatoprotective and osteoprotective effects, making it a valuable tool for research in inflammation and cancer biology.